The Possibility Of VEGF As A Marker To Evaluate The Effectiveness Of Intervention Therapy To Hepatorcellular Carcinoma

Objective: Primary hepatorcellular carcinoma is one of the most common and severe malignancies all over the world, particularly in China. Most patients have lost the opportunities of surgery treatment, when diagnosed because the tumors have arrived at the advanced stage, otherway, many of them occurred in cirrhosis liver. So non-surgery method is becoming more and more important. Intervention therapy is a main non-surgery method. Transarterial chemoembolization (TACE) and radiofrequency ablation (RFA), as two representative ones, have been widely practiced clinically with successful effectiveness. However, there are no satisfied markers to evaluate effectiveness of the two methods. Vascular endothelial growth factor (VEGF) is the strongest vascular growth factor known in body, and many cells, particularly cancer cells, can secrete VEGF after receiving the stimulations such as hypoxia etc. So the blood level of VEGF could reflect the necrotic degree of cells that is secreting the factor. In this study, we want to explore the feasibility of VEGF as a marker in judging the effectiveness of the intervention therapy to HCC..Methods: Peripheral blood samples were taken at the 1st day before the therapy and at the1st day, 3rd day, 7th day, 14th day, and the 28th day after intervention therapy, respectively, from 16 patients with HCC including 13 patients receiving TACE and 3 receiving with RFA treatment. The quantitative sandwich enzyme-linked immunosorbent assay (ELISA) was used to detect the plasma VEGF level. SPSS13.0 statistic...